Calmer Co Posts Record $910k Month as US FDA Ruling Opens Kava Market

The Calmer Co International Limited (ASX: CCO) has delivered its strongest monthly performance since listing, recording $910,767 in unaudited December 2025 revenue. The result was driven by record wholesale channel sales of $340,131, with year-to-date wholesale revenue in the first half of FY26 already surpassing the company’s entire FY25 annual wholesale performance. The milestone comes as recent US Food and Drug Administration (FDA) regulatory clarity positions the kava producer to accelerate retail expansion in a market where 21 million Americans now consume kava products.

What Drove Calmer Co’s Record $910k Monthly Revenue?

The December result reflects momentum across three core revenue channels: Australian grocery distribution, US Amazon sales, and business-to-business (B2B) wholesale ingredient supply. Wholesale emerged as the standout performer, with the $340,131 December figure representing the channel’s strongest single month on record. This performance is particularly significant given year-to-date wholesale sales have exceeded total FY25 annual wholesale revenue within just six months of the current financial year.

Australian retail performance remained robust through continued distribution of Fiji Kava® products across Coles and Woolworths supermarket networks. In the United States, Amazon sales growth was supported by an expanding product range including tinctures, capsules, and flavoured kava shots. B2B ingredient sales benefited from increasing demand for high-kavalactone kava extracts from global manufacturing partners seeking traceable, quality-controlled supply.

The improved channel mix contributed to enhanced margin profiles. Wholesale ingredient sales typically carry different economics compared to direct-to-consumer retail, while the combination of established grocery distribution and growing digital channels provides revenue diversification that reduces single-point concentration risk.

For investors, the wholesale channel trajectory signals enterprise-level demand for traceable kava ingredients, whilst multi-channel performance demonstrates operational leverage across both consumer-facing and ingredient supply business models.

What Does FDA Kava Regulation Mean for Calmer Co?

The FDA has confirmed that traditionally prepared kava beverages qualify as food under federal law, rather than dietary supplements. This regulatory clarification establishes a dual-category framework: brewed kava beverages are classified as conventional food products, whilst tinctures, capsules, and flavoured kava shots remain within the dietary supplement regulatory pathway.

For kava producers, the food classification provides a clearer compliance framework for traditionally prepared beverages, potentially enabling broader retail distribution channels that may have previously been cautious due to regulatory ambiguity. The dietary supplement category, which covers the majority of CCO’s current US product range, operates under its own established regulatory structure administered by the FDA’s Centre for Food Safety and Applied Nutrition.

Traditionally prepared kava beverages refer to products made using water-based extraction methods consistent with customary Pacific Island preparation techniques. The FDA’s position recognises these products as distinct from concentrated extracts or non-traditional formulations. This distinction matters because food products follow different manufacturing, labelling, and compliance requirements compared to dietary supplements, though both categories are subject to FDA oversight.

“This landmark clarification provides regulatory certainty and a clearer compliance pathway for kava products in the world’s largest consumer market, de-risking broader retail distribution and digitally-led growth,” said Zane Yoshida, Founder and CEO.

The dual-category framework aligns with CCO’s existing multi-format portfolio strategy. The company already markets both traditionally prepared beverages and supplement-format products (tinctures, capsules, flavoured shots) through its US Amazon channel. With 21 million Americans reported to consume kava, the regulatory clarity removes compliance uncertainty that may have constrained retail partnerships or digital marketing strategies.

For investors, FDA confirmation reduces regulatory overhang in the world’s largest consumer market, potentially accelerating retail expansion timelines without the compliance risk that accompanies ambiguous categorisation.

How is Calmer Co Performing in the Kava Market?

The record $910,767 monthly revenue validates CCO’s vertically-integrated “farm-to-shelf” business model, which provides supply chain control from Pacific Island sourcing through to finished product distribution. This operational structure enables the company to capture value across multiple points in the kava value chain, supplying both consumer products through retail and e-commerce channels, and high-kavalactone extracts to manufacturing partners requiring traceable ingredients.

The wholesale channel’s trajectory illustrates this dual-market positioning. With the first half of FY26 already exceeding FY25’s full-year wholesale performance, the B2B ingredient business is scaling independently of consumer-facing retail channels. This suggests enterprise demand for quality-controlled kava supply amongst manufacturers formulating functional beverages, supplements, or wellness products.

CCO’s global distribution footprint spans Australia (Coles and Woolworths grocery networks), the United States (Amazon digital platform), New Zealand, China, and Pacific Island markets. The brand portfolio includes Fiji Kava®, Taki Mai®, and Danodan Hempworks, addressing different product formats and consumer preferences across these geographies.

The company’s competitive positioning is supported by several structural factors:

1. Vertically-integrated supply chain providing farm-to-shelf traceability and quality control over raw material sourcing

2. Dual-market presence capturing both consumer product demand (B2C) and ingredient supply requirements (B2B)

3. Multi-format product portfolio aligned with regulatory frameworks in key markets (food-classified beverages and dietary supplement formats)

4. Established retail distribution partnerships in two mature consumer markets (Australia and USA)

Management indicated the December result supports the company’s trajectory toward breakeven in FY26, with the improved channel mix and margin profile contributing to the pathway toward sustainable profitability. For investors, supply chain ownership combined with regulatory clarity in the US market positions CCO to capture margin across the value chain whilst competitors operating solely in finished products or ingredient supply remain constrained to single revenue models.

What’s Next for Calmer Co?

Management has indicated confidence in the company’s trajectory toward breakeven and sustained profitable growth through FY26. The record December performance, combined with wholesale momentum that has seen the first half of FY26 exceed FY25’s full-year total in that channel, provides operational evidence supporting this outlook.

The FDA regulatory clarity creates potential for accelerated US retail expansion. With 21 million Americans consuming kava and a clearer compliance pathway now established, the company may pursue traditional grocery distribution partnerships that previously faced regulatory uncertainty. The existing Amazon presence provides a foundation for scaled digital distribution, whilst the multi-format product portfolio (food-classified beverages and dietary supplement formats) enables market entry across both regulatory categories.

Near-term catalysts include:

• Further US retail expansion enabled by FDA regulatory framework clarity
• Continued wholesale channel growth driven by B2B ingredient demand from manufacturing partners
• Potential margin expansion through improved channel mix as higher-margin wholesale sales scale
• Amazon SKU range expansion introducing new formats and flavours to the US dietary supplement category

The combination of record revenue performance, regulatory tailwinds in the world’s largest consumer market, and year-to-date wholesale sales already exceeding the prior full year positions the company to capitalise on structural growth in the functional beverage category. Management’s emphasis on the vertically-integrated farm-to-shelf model suggests confidence in supply chain capacity to support scaling operations without third-party dependency constraints.

For investors, FY26 represents a potential inflection year where operational leverage from established distribution channels, regulatory de-risking in the US market, and dual-revenue stream diversification (consumer products and B2B ingredients) converge to support the pathway toward sustainable profitability. The December result provides quantifiable evidence of execution against this strategic framework.

Ready To Explore Calmer Co’s Record-Breaking Growth?

Calmer Co’s strongest monthly revenue of $910,767 highlights robust expansion across wholesale, retail, and digital channels, supported by favourable FDA regulatory clarity in the US market. This growth underpins a clear pathway to sustained profitability through FY26 for investors seeking exposure to an integrated kava producer.

Discover detailed insights and investment potential by visiting the Calmer Co investor centre to explore its unique farm-to-shelf model and multi-channel market strategy.